AZD5423   Click here for help

GtoPdb Ligand ID: 13017

Synonyms: AZD-5423 | compound 1b [PMID: 28937774]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD5423 was originally reported as a selective glucocorticoid receptor modulator (SGRM) and investigated for anti-inflammatory potential [1,3]. Using a virtual screening strategy it has subsequently been shown to inhibit activation of receptor interacting serine/threonine kinase 3 (RIPK3) [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 63.16
Molecular weight 487.45
XLogP 3.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]([C@@H](C1=CC=CC(=C1)OC)OC2=CC3=C(C=C2)N(C4=CC=C(C=C4)F)N=C3)NC(=O)C(F)(F)F
Isomeric SMILES C[C@@H]([C@@H](C1=CC(=CC=C1)OC)OC2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)NC(=O)C(F)(F)F
InChI InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1
InChI Key FCNQMDSJHADDFT-WNSKOXEYSA-N
No information available.
Summary of Clinical Use Click here for help
AZD5423 was advanced to clinical evaluation, but its development in asthma and COPD was discontinued.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01555099 Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol Phase 2 Interventional AstraZeneca
NCT01225549 The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen Phase 2 Interventional AstraZeneca